Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Net Income | -184.65M | -144.34M | -82.28M | -67.04M | -19.66M |
| Total Depreciation and Amortization | 361.10M | 372.61M | 312.84M | 386.87M | 317.95M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 523.86M | 495.29M | 554.01M | 426.08M | 459.05M |
| Change in Net Operating Assets | -93.29M | 14.08M | -35.09M | 41.55M | 19.05M |
| Cash from Operations | 607.03M | 737.65M | 749.49M | 787.45M | 776.39M |
| Capital Expenditure | -215.74M | -219.15M | -205.82M | -208.96M | -213.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -405.01M | -- | 0.00 | 0.00 | -5.48M |
| Divestitures | 60.10M | 17.44M | 17.44M | 17.44M | 17.44M |
| Other Investing Activities | -11.04M | -7.61M | -4.24M | 11.27M | -3.59M |
| Cash from Investing | -571.69M | -209.32M | -192.62M | -180.25M | -204.77M |
| Total Debt Issued | 1.72B | 1.23B | 1.18B | 1.30B | 1.20B |
| Total Debt Repaid | -1.56B | -1.35B | -1.32B | -1.39B | -1.35B |
| Issuance of Common Stock | 1.94M | 714.00K | 771.00K | 1.55M | 2.37M |
| Repurchase of Common Stock | -215.83M | -360.67M | -360.70M | -461.39M | -462.96M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -37.84M | -54.98M | -58.19M | -65.43M | -60.37M |
| Cash from Financing | -83.68M | -536.73M | -560.74M | -615.66M | -674.60M |
| Foreign Exchange rate Adjustments | 14.81M | 18.83M | 1.45M | 12.19M | -3.82M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.53M | 10.43M | -2.42M | 3.74M | -106.81M |